echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > LVYE pharmaceutical completed the acquisition of 245 million euro aceno transdermal drug business in Switzerland

    LVYE pharmaceutical completed the acquisition of 245 million euro aceno transdermal drug business in Switzerland

    • Last Update: 2016-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: 21st century economic report from December 1, 2016 to February 2, 21st century economic report reporter learned from green leaf Pharmaceutical Group (2186 HK) that green leaf pharmaceutical group had officially completed the acquisition of the leading transdermal drug delivery system business under the Swiss well-known enterprise acino on November 30 It took only four months for LVYE Pharmaceutical Group to sign a contract with Swiss acino company with 245 million euros on July 25 to complete all the acquisitions This is also another attempt by domestic pharmaceutical companies to acquire overseas high-quality targets In this regard, the management of LVYE Pharmaceutical Group said that the successful delivery of transdermal drug delivery system business is a great inspiration for LVYE pharmaceutical, fully reflecting the core of the company's globalization strategy, that is, to promote the Chinese market and the international market to keep pace with each other by means of cooperative M & a, R & D innovation, brand marketing and international quality standards It is understood that the acquired target group is one of the largest independent transdermal system manufacturers in Europe Its product portfolio focuses on specialized transdermal patch products with complex manufacturing processes and high profits, such as central nervous system, pain and hormone Several of its products with high manufacturing difficulties have been successfully launched, such as gabardine patch for mild to moderate Alzheimer's disease and pain Buprenorphine patch and fentanyl patch, as well as contraceptive patch According to the third-party research data, in 2014, the sales revenue of the global transdermal patch market was 5.095 billion euros, which is predicted to reach 6.4 billion euros by 2020, with a compound annual growth rate of more than 4% The global market of transdermal drug delivery business is huge and has strong potential growth The trend of global population aging will increase the demand of chronic disease management, as well as in emerging markets According to the white paper data of China's medical and health services, there are more than 260 million chronic disease patients in China According to the official of the health and Family Planning Commission at the end of October, nearly 150 million of China's 222 million elderly have chronic diseases Therefore, it is undoubtedly a huge market for the transdermal drug delivery business, which is mainly used in the treatment of chronic diseases LVYE said that in the next step, it will fully combine its experience and advantages in the Chinese market to open up new market opportunities and development space for transdermal drug delivery business In the view of the insiders, the acquisition of such a European company with leading professional level in the subdivision field by LVYE Pharmaceutical Group will greatly improve the R & D and production level of LVYE pharmaceutical in the field of new preparations, enrich the product line, enhance the competition level in the core field, and improve the international level of the company in R & D, production, international registration, market promotion, etc Step to explore the global market While bringing stable business income, it will also bring significant development opportunities for the group According to the data, LVYE Pharmaceutical Group focuses on the R & D, production and marketing of innovative drugs in the fields of tumor, cardiovascular, metabolism and central nervous system At present, it has 30 listed products, 21 new drug products under research in China and 7 new drug products under research overseas, of which 5 Products have entered the clinical trial stage in the United States, and have been listed and sold in many provinces, autonomous regions and municipalities directly under the central government, as well as in many overseas countries and regions.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.